<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487067</url>
  </required_header>
  <id_info>
    <org_study_id>ML42243</org_study_id>
    <nct_id>NCT04487067</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista</brief_title>
  <acronym>AMETHISTA</acronym>
  <official_title>A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety
      and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have
      received no prior systemic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 3-5 NCI CTCAE v.5 Bleeding/Haemorrhage</measure>
    <time_frame>Up to approximately 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Overall survival (OS) is defined as the time from initiation of study treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Number of participants with adverse events with severity determined according to NCI CTCAE v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Objective response rate (ORR) is defined as a complete or partial response, as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Time to progression (TTP) is defined as the time from initiation of study treatment to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Duration of response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Progression Survival (PPS)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Post-progression survival (PPS) is defined as the time from the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Starting Second or Further Lines of Treatment</measure>
    <time_frame>Up to approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>Participant self-reported symptomatic Adverse Events (AEs) using National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1200 mg IV infusion q3w</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15 mg/kg IV Q3W</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable HCC with diagnosis confirmed by histology, with a biopsy within 6 months
             from recruitment;

          -  Disease that is not amenable to curative surgical and/or locoregional therapies, or
             progressive disease after surgical and /or locoregional therapies;

          -  No prior systemic therapy for HCC;

          -  At least one measurable untreated lesion;

          -  Patients who received prior local therapyare eligible provided the target lesion(s)
             have not been previously treated with local therapy or the target lesion(s) within the
             field of local therapy have subsequently progressed in accordance with RECIST version
             1.1;

          -  ECOG Performance Status of 0 or 1 within 7 days prior to recruitment;

          -  Child-Pugh class A within 7 days prior to recruitment;

          -  Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices
             (small to large) must be assessed. In case of varices at high risk of bleeding
             (corresponding to medium (F2) or large (F3) varices, or F1 varices with cherry red
             spots or red wale marking) prophylatic treatment per local standard of care must be
             adopted prior to enrollment. Patients who have undergone an EGD within 6 months of
             prior to initiation of study treatment do not need to repeat the procedure provided
             they had no varices at high risk of bleeding;

          -  Adequate hematologic and end-organ function

          -  Resolution of any acute, clinically significant treatment-related toxicity from prior
             therapy to Grade &lt;= 1 prior to study entry, with the exception of alopecia

          -  Negative HIV test at screening with the following exception: patients with a positive
             HIV test at screening are eligible provided they are stable on anti-retroviral
             therapy, have a CD4 count ≥200µL, and have an undetectable viral load;

          -  In patients with viral HCC, documented virology status of hepatitis, as confirmed by
             screening HBV and HCV serology test;

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods with a failure rate of &lt; 1% per
             year during the treatment period and for at least 5 months after the last dose of
             atezolizumab and 6 months after the last dose of bevacizumab. Women must refrain from
             donating eggs during this same period.

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm.

        Exclusion Criteria:

          -  History of leptomeningeal disease or brain metastases;

          -  Active or history of autoimmune disease or immune deficiency;

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography (CT) scan;

          -  Known active tuberculosis;

          -  Significant cardiovascular disease within 3 months prior to initiation of study
             treatment, unstable arrhythmia, or unstable angina;

          -  History of malignancy other than HCC within 5 years prior to screening, with the
             exception of malignancies with a negligible risk of metastasis or death;

          -  Prior allogeneic stem cell or solid organ transplantation;

          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment
             or within at least 5 months after the last dose of atezolizumab and 6 months after the
             last dose of bevacizumab;

          -  Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC;

          -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or
             high-risk for bleeding;

          -  A prior bleeding event due to oesophageal and/or gastric varices within 6 months prior
             to initiation of study treatment;

          -  Clinically evident ascites;

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases;

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures;

          -  Uncontrolled or symptomatic hypercalcemia;

          -  Inadequately controlled arterial hypertension;

          -  Significant vascular disease within 6 months prior to initiation of study treatment;

          -  History of haemoptysis;

          -  Evidence of bleeding diathesis or significant coagulopathy;

          -  History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation,
             or intra-abdominal abscess within 6 months prior to initiation of study treatment;

          -  History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction
             including sub-occlusive disease related to the underlying disease or requirement for
             routine parenteral hydration, parenteral nutrition, or tube feeding prior to
             initiation of study treatment;

          -  Metastatic disease that involves major airways or blood vessels, or centrally located
             mediastinal tumor masses of large volume;

          -  Local therapy to liver within 28 days prior to initiation of study treatment or
             non-recovery from side effects of any such procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML42243 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale del Mare; UOC di Oncologia</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi)</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova; Oncologia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U Careggi</name>
      <address>
        <city>Florence</city>
        <state>Toscana</state>
        <zip>50124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

